Your browser is no longer supported. Please, upgrade your browser.
Settings
SAVA Cassava Sciences, Inc. daily Stock Chart
SAVA [NASD]
Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-0.22 Insider Own10.10% Shs Outstand15.96M Perf Week1.52%
Market Cap117.63M Forward P/E54.59 EPS next Y0.14 Insider Trans62.16% Shs Float13.69M Perf Month-4.66%
Income-3.80M PEG- EPS next Q-0.13 Inst Own39.20% Short Float12.70% Perf Quarter480.31%
Sales- P/S- EPS this Y66.30% Inst Trans-5.24% Short Ratio0.33 Perf Half Y519.33%
Book/sh1.02 P/B7.23 EPS next Y141.90% ROA-19.70% Target Price9.00 Perf Year558.04%
Cash/sh1.12 P/C6.61 EPS next 5Y- ROE-20.70% 52W Range1.00 - 10.95 Perf YTD41.73%
Dividend- P/FCF- EPS past 5Y-16.30% ROI- 52W High-32.69% Beta2.53
Dividend %- Quick Ratio20.10 Sales past 5Y- Gross Margin- 52W Low637.00% ATR0.65
Employees9 Current Ratio20.10 Sales Q/Q- Oper. Margin- RSI (14)52.01 Volatility7.45% 9.22%
OptionableYes Debt/Eq0.00 EPS Q/Q61.70% Profit Margin- Rel Volume0.16 Prev Close7.62
ShortableYes LT Debt/Eq0.00 EarningsMar 03 BMO Payout- Avg Volume5.21M Price7.37
Recom2.00 SMA20-5.39% SMA5014.27% SMA200188.10% Volume831,086 Change-3.28%
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Feb-11-20 08:15AM  Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimers Disease (JPAD) GlobeNewswire
Jan-28-20 08:15AM  Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimers Disease GlobeNewswire +21.12%
Jan-10-20 09:33AM  The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences Zacks
Jan-09-20 06:19AM  Buy Multibagger Stocks as Odds of a Rally Are High in 2020 Zacks -7.79%
Jan-08-20 11:23AM  Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics Zacks +11.69%
Jan-07-20 09:03AM  5 Stocks With Recent Price Strength for Spectacular Returns Zacks -10.78%
Jan-06-20 05:05AM  Are Insiders Buying Cassava Sciences, Inc. (NASDAQ:SAVA) Stock? Simply Wall St. -10.57%
Jan-03-20 10:36AM  Company News For Jan 3, 2020 Zacks +34.03%
08:22AM  The Zacks Analyst Blog Highlights: EverQuote, Cassava Sciences, Fulgent Genetics, Teekay Tankers and Cue Biopharma Zacks
Jan-02-20 10:19AM  5 Stocks to Soar in 2020 After Solid Gains in 2019 Zacks +38.46%
08:38AM  Cassava's stock rises 33% MarketWatch
Dec-27-19 02:19PM  Biotech Rally Sends Nasdaq to 9000: ETFs in Focus Zacks +29.28%
Dec-10-19 07:42AM  Top Ranked Momentum Stocks to Buy for December 10th Zacks
Dec-06-19 03:08PM  Alzheimers expert says more clinical trials are needed for controversial Biogen drug MarketWatch
10:58AM  Cassava stock is up on Alzheimer's data MarketWatch
07:39AM  The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga
Dec-05-19 09:00PM  Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimers Disease at CTAD 2019 GlobeNewswire
Dec-04-19 09:26AM  Top Ranked Momentum Stocks to Buy for December 4th Zacks
Dec-01-19 09:30AM  The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-05-19 12:06PM  We Think Cassava Sciences (NASDAQ:SAVA) Can Easily Afford To Drive Business Growth Simply Wall St.
Oct-29-19 08:15AM  Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results GlobeNewswire +5.51%
Oct-24-19 08:30AM  Cassava Sciences Clinical Results in Alzheimers Selected as Late-Breaking News at CTAD 2019 GlobeNewswire +5.99%
Sep-20-19 10:02AM  6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day Zacks -8.46%
Sep-16-19 08:30AM  Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimers Patients GlobeNewswire
Sep-09-19 02:42PM  Failure of Alzheimers Disease Study Creates a New Penny Stock Bloomberg -12.86%
12:17PM  A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019 Benzinga
07:30AM  Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimers Patients GlobeNewswire
Sep-06-19 11:50AM  How Cassava Sciences, Inc. (NASDAQ:SAVA) Can Impact Your Portfolio Volatility Simply Wall St. +10.24%
Sep-03-19 08:30AM  Cassava Sciences to Present at H.C. Wainwrights 21st Annual Global Investment Conference GlobeNewswire +17.86%
Aug-12-19 08:30AM  Cassava Sciences Announces Second Quarter 2019 Financial Results GlobeNewswire -6.77%
Jul-08-19 02:51PM  What Kind Of Shareholder Owns Most Cassava Sciences, Inc. (NASDAQ:SAVA) Stock? Simply Wall St.
Jun-18-19 08:30AM  Cassava Sciences to Present at Maxim Groups Conference on Alzheimers Disease GlobeNewswire
May-28-19 08:29AM  Cassava Sciences Announces New Website Launch GlobeNewswire
May-23-19 04:35PM  Weekly CFO Buys Highlight GuruFocus.com
May-16-19 10:36AM  Cassava Sciences, Inc. (NASDAQ:SAVA) Insiders Increased Their Holdings Simply Wall St.
Apr-29-19 08:30AM  Cassava Sciences Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-15-19 08:30AM  Cassava Sciences Completes Patient Enrollment for a Phase 2a Study in Patients with Alzheimers Disease GlobeNewswire
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBIER REMIPresident and CEODec 31Buy5.53100,000553,0001,068,855Dec 31 04:10 PM
BARBIER REMIPresident and CEODec 26Buy4.1510,00041,500968,855Dec 26 04:03 PM
ROBERTSON SANFORDDirectorDec 20Buy2.20423,788932,334662,623Dec 20 04:11 PM
Schoen EricChief Financial OfficerDec 19Buy1.885,3009,96415,300Dec 19 06:06 PM
ROBERTSON SANFORDDirectorDec 19Buy1.8676,212141,754238,835Dec 19 06:04 PM
BARBIER REMIPresident and CEODec 18Buy1.652,5994,2882,599Dec 20 04:13 PM